GSK Is Parting With Its ‘Rare Disease Gene Therapy’ Unit Instead
Walmsley progressively moves on her promise of reshaping GSK’s portfolio in a strategic overhaul of the company whereby focusing on oncology.
gene-based cell therapy
Walmsley progressively moves on her promise of reshaping GSK’s portfolio in a strategic overhaul of the company whereby focusing on oncology.
